Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Genevieve Losonsky

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Procedures

Disorders

Anatomy

Feces

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
87
Levine, Myron
42
Tacket, Carol
32
Wasserman, Steven
25
Nataro, James
23
Edelman, Robert
21
Kotloff, Karen
19
Kaper, James
15
Sztein, Marcelo
14
Cryz, Stanley
11
Morris, Glenn
11
Rennels, Margaret
8
Noriega, FR
8
Tall, BD
7
Barry, Eileen
6
Pichichero, Michael

Sign-in to see all Coauthors

Publications

TOP 3
Lagos Rosanna; Devincenzo John P; Muñoz Alma; Hultquist Micki; Suzich Joann; Connor Edward M; Losonsky Genevieve A
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (rsv)-specific humanized monoclonal antibody, when administered to rsv-infected children.
Gomez Margarita; Mufson Maurice A; Dubovsky Filip; Knightly Conor; Zeng Wen; Losonsky Genevieve
Phase-I study medi-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
Abarca Katia; Jung Elizabeth; Fernández Pilar; Zhao Liang; Harris Brian; Connor Edward M; Losonsky Genevieve A;
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Genevieve Losonsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lagos Rosanna; Devincenzo John P; Muñoz Alma; Hultquist Micki; Suzich Joann; Connor Edward M; Losonsky Genevieve A
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (rsv)-specific humanized monoclonal antibody, when administered to rsv-infected children.
The Pediatric infectious disease journal 2009;28(9):835-7.
2009: Gomez Margarita; Mufson Maurice A; Dubovsky Filip; Knightly Conor; Zeng Wen; Losonsky Genevieve
Phase-I study medi-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
The Pediatric infectious disease journal 2009;28(7):655-8.
2009: Abarca Katia; Jung Elizabeth; Fernández Pilar; Zhao Liang; Harris Brian; Connor Edward M; Losonsky Genevieve A;
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
The Pediatric infectious disease journal 2009;28(4):267-72.
2008: Tang Roderick S; Spaete Richard R; Thompson Mark W; MacPhail Mia; Guzzetta Jeanne M; Ryan Patricia C; Reisinger Keith; Chandler Patricia; Hilty Milo; Walker Robert E; Gomez Margarita M; Losonsky Genevieve A
Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Vaccine 2008;26(50):6373-82.
2008: Wu H; Pfarr D S; Losonsky G A; Kiener P A
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
Current topics in microbiology and immunology 2008;317():103-23.
2003: Tacket Carol O; Sztein Marcelo B; Losonsky Genevieve A; Wasserman Steven S; Estes Mary K
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.
Clinical immunology (Orlando, Fla.) 2003;108(3):241-7.
2003: Pasetti Marcela F; Barry Eileen M; Losonsky Genevieve; Singh Mahender; Medina-Moreno Sandra M; Polo John M; Ulmer Jeffrey; Robinson Harriet; Sztein Marcelo B; Levine Myron M
Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.
Journal of virology 2003;77(9):5209-17.
2003: Losonsky Genevieve A; Kotloff Karen L; Walker Richard I
B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals.
Vaccine 2003;21(5-6):562-5.
2003: Barry Eileen M; Altboum Zeev; Losonsky Genevieve; Levine Myron M
Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains.
Vaccine 2003;21(5-6):333-40.
2002: Campbell James D; Lagos Rosanna; Levine Myron M; Losonsky Genevieve A
Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants.
The Pediatric infectious disease journal 2002;21(9):822-6.
2002: Kotloff Karen L; Taylor David N; Sztein Marcelo B; Wasserman Steven S; Losonsky Genevieve A; Nataro James P; Venkatesan Malabi; Hartman Antoinette; Picking William D; Katz David E; Campbell James D; Levine Myron M; Hale Thomas L
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.
Infection and immunity 2002;70(4):2016-21.
2001: Kotloff K L; Sztein M B; Wasserman S S; Losonsky G A; DiLorenzo S C; Walker R I
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.
Infection and immunity 2001;69(6):3581-90.
2001: Altboum Z; Barry E M; Losonsky G; Galen J E; Levine M M
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Infection and immunity 2001;69(5):3150-8.
2001: Kotloff K L; Wasserman S S; Losonsky G A; Thomas W; Nichols R; Edelman R; Bridwell M; Monath T P
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.
Infection and immunity 2001;69(2):988-95.
2000: Tacket C O; Galen J; Sztein M B; Losonsky G; Wyant T L; Nataro J; Wasserman S S; Edelman R; Chatfield S; Dougan G; Levine M M
Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.
Clinical immunology (Orlando, Fla.) 2000;97(2):146-53.
2000: Cooper P J; Chico M E; Losonsky G; Sandoval C; Espinel I; Sridhara R; Aguilar M; Guevara A; Guderian R H; Levine M M; Griffin G E; Nutman T B
Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.
The Journal of infectious diseases 2000;182(4):1199-206.
2000: Koprowski H; Levine M M; Anderson R J; Losonsky G; Pizza M; Barry E M
Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.
Infection and immunity 2000;68(9):4884-92.
2000: Tacket C O; Mason H S; Losonsky G; Estes M K; Levine M M; Arntzen C J
Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes.
The Journal of infectious diseases 2000;182(1):302-5.
2000: Tacket C O; Sztein M B; Losonsky G; Abe A; Finlay B B; McNamara B P; Fantry G T; James S P; Nataro J P; Levine M M; Donnenberg M S
Role of EspB in experimental human enteropathogenic Escherichia coli infection.
Infection and immunity 2000;68(6):3689-95.
2000: Rennels M B; Englund J A; Bernstein D I; Losonsky G A; Anderson E L; Pichichero M E; Munoz F M; Wolff M C
Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
The Pediatric infectious disease journal 2000;19(5):417-23.
2000: Tacket C O; Sztein M B; Wasserman S S; Losonsky G; Kotloff K L; Wyant T L; Nataro J P; Edelman R; Perry J; Bedford P; Brown D; Chatfield S; Dougan G; Levine M M
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
Infection and immunity 2000;68(3):1196-201.
2000: Kotloff K L; Noriega F R; Samandari T; Sztein M B; Losonsky G A; Nataro J P; Picking W D; Barry E M; Levine M M
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.
Infection and immunity 2000;68(3):1034-9.
2000: Samandari T; Kotloff K L; Losonsky G A; Picking W D; Sansonetti P J; Levine M M; Sztein M B
Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(4):2221-32.
2000: Rennels M B; Deloria M A; Pichichero M E; Losonsky G A; Englund J A; Meade B D; Anderson E L; Steinhoff M C; Edwards K M
Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
Pediatrics 2000;105(1):e12.
1999: Cohen M B; Giannella R A; Losonsky G A; Lang D R; Parker S; Hawkins J A; Gunther C; Schiff G A
Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.
Infection and immunity 1999;67(12):6346-9.
1999: Tacket C O; Cohen M B; Wasserman S S; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper J B; Cryz S J; Giannella R A; Schiff G; Levine M M
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Infection and immunity 1999;67(12):6341-5.
1999: Tacket C O; Losonsky G; Livio S; Edelman R; Crabb J; Freedman D
Lack of prophylactic efficacy of an enteric-coated bovine hyperimmune milk product against enterotoxigenic Escherichia coli challenge administered during a standard meal.
The Journal of infectious diseases 1999;180(6):2056-9.
1999: Losonsky G A; Fantry G T; Reymann M; Lim Y
Validation of a gastrointestinal explant system for measurement of mucosal antibody production.
Clinical and diagnostic laboratory immunology 1999;6(6):803-7.
1999: Lagos R; Fasano A; Wasserman S S; Prado V; San Martin O; Abrego P; Losonsky G A; Alegria S; Levine M M
Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.
The Journal of infectious diseases 1999;180(5):1709-12.
1999: Lagos R; San Martin O; Wasserman S S; Prado V; Losonsky G A; Bustamante C; Levine M M
Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
The Pediatric infectious disease journal 1999;18(7):624-30.
1999: Michetti P; Kreiss C; Kotloff K L; Porta N; Blanco J L; Bachmann D; Herranz M; Saldinger P F; Corthésy-Theulaz I; Losonsky G; Nichols R; Simon J; Stolte M; Ackerman S; Monath T P; Blum A L
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.
Gastroenterology 1999;116(4):804-12.
1999: Taylor D N; Sanchez J L; Castro J M; Lebron C; Parrado C M; Johnson D E; Tacket C O; Losonsky G A; Wasserman S S; Levine M M; Cryz S J
Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.
Infection and immunity 1999;67(4):2030-4.
1999: Losonsky G A; Wasserman S S; Stephens I; Mahoney F; Armstrong P; Gumpper K; Dulkerian S; West D J; Gewolb I H
Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.
Pediatrics 1999;103(2):E14.
1998: Lagos R; Valenzuela M T; Levine O S; Losonsky G A; Erazo A; Wasserman S S; Levine M M
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.
Lancet 1998;351(9114):1472-6.
1998: Tacket C O; Mason H S; Losonsky G; Clements J D; Levine M M; Arntzen C J
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato.
Nature medicine 1998;4(5):607-9.
1998: Sack D A; Tacket C O; Cohen M B; Sack R B; Losonsky G A; Shimko J; Nataro J P; Edelman R; Levine M M; Giannella R A; Schiff G; Lang D
Validation of a volunteer model of cholera with frozen bacteria as the challenge.
Infection and immunity 1998;66(5):1968-72.
1998: Tacket C O; Taylor R K; Losonsky G; Lim Y; Nataro J P; Kaper J B; Levine M M
Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection.
Infection and immunity 1998;66(2):692-5.
1998: Donnenberg M S; Tacket C O; Losonsky G; Frankel G; Nataro J P; Dougan G; Levine M M
Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge.
Infection and immunity 1998;66(1):52-8.
1998: Perry R T; Plowe C V; Koumaré B; Bougoudogo F; Kotloff K L; Losonsky G A; Wasserman S S; Levine M M
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Bulletin of the World Health Organization 1998;76(1):63-71.
1997: Taylor D N; Tacket C O; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro J P; Kaper J B; Wasserman S S; Edelman R; Levine M M; Cryz S J
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
Infection and immunity 1997;65(9):3852-6.
1997: Tacket C O; Kelly S M; Schödel F; Losonsky G; Nataro J P; Edelman R; Levine M M; Curtiss R
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.
Infection and immunity 1997;65(8):3381-5.
1997: Tacket C O; Kotloff K L; Losonsky G; Nataro J P; Michalski J; Kaper J B; Edelman R; Levine M M
Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111.
The American journal of tropical medicine and hygiene 1997;56(5):533-7.
1997: Losonsky G A; Lim Y; Motamedi P; Comstock L E; Johnson J A; Morris J G; Tacket C O; Kaper J B; Levine M M
Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.
Clinical and diagnostic laboratory immunology 1997;4(3):264-9.
1997: Galen J E; Gomez-Duarte O G; Losonsky G A; Halpern J L; Lauderbaugh C S; Kaintuck S; Reymann M K; Levine M M
A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.
Vaccine 1997;15(6-7):700-8.
1997: Levine M M; Galen J; Barry E; Noriega F; Tacket C; Sztein M; Chatfield S; Dougan G; Losonsky G; Kotloff K
Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.
Behring Institute Mitteilungen 1997;(98):120-3.
1997: Tacket C O; Sztein M B; Losonsky G A; Wasserman S S; Nataro J P; Edelman R; Pickard D; Dougan G; Chatfield S N; Levine M M
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.
Infection and immunity 1997;65(2):452-6.
1996: Morris J G; Sztein M B; Rice E W; Nataro J P; Losonsky G A; Panigrahi P; Tacket C O; Johnson J A
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans.
The Journal of infectious diseases 1996;174(6):1364-8.
1996: Levine O S; Lagos R; Losonsky G A; San Martin O; Abrego P; Bustamante C; Wasserman S S; Levine M M
No adverse impact on protection against pertussis from combined administration of Haemophilus influenza type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe.
The Journal of infectious diseases 1996;174(6):1341-4.
1996: Kotloff K L; Noriega F; Losonsky G A; Sztein M B; Wasserman S S; Nataro J P; Levine M M
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
Infection and immunity 1996;64(11):4542-8.
1996: Barry E M; Gomez-Duarte O; Chatfield S; Rappuoli R; Pizza M; Losonsky G; Galen J; Levine M M
Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.
Infection and immunity 1996;64(10):4172-81.
1996: Noriega F R; Losonsky G; Lauderbaugh C; Liao F M; Wang J Y; Levine M M
Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
Infection and immunity 1996;64(8):3055-61.
1996: Noriega F R; Losonsky G; Wang J Y; Formal S B; Levine M M
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
Infection and immunity 1996;64(1):23-7.
1996: Losonsky G A; Yunyongying J; Lim V; Reymann M; Lim Y L; Wasserman S S; Levine M M
Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.
Infection and immunity 1996;64(1):10-5.
1995: Kotloff K L; Nataro J P; Losonsky G A; Wasserman S S; Hale T L; Taylor D N; Sadoff J C; Levine M M
A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
Vaccine 1995;13(16):1488-94.
1995: Tacket C O; Losonsky G; Nataro J P; Comstock L; Michalski J; Edelman R; Kaper J B; Levine M M
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
The Journal of infectious diseases 1995;172(3):883-6.
1995: Morris J G; Losonsky G E; Johnson J A; Tacket C O; Nataro J P; Panigrahi P; Levin M M
Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.
The Journal of infectious diseases 1995;171(4):903-8.
1995: Kotloff K L; Losonsky G A; Nataro J P; Wasserman S S; Hale T L; Taylor D N; Newland J W; Sadoff J C; Formal S B; Levine M M
Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
Vaccine 1995;13(5):495-502.
1995: Lagos R; Avendaño A; Prado V; Horwitz I; Wasserman S; Losonsky G; Cryz S; Kaper J B; Levine M M
Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
Infection and immunity 1995;63(2):707-9.
1995: Tacket C O; Losonsky G; Nataro J P; Wasserman S S; Cryz S J; Edelman R; Levine M M
Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1995;89(1):75-7.
1994: Noriega F R; Wang J Y; Losonsky G; Maneval D R; Hone D M; Levine M M
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
Infection and immunity 1994;62(11):5168-72.
1994: Tacket C O; Reid R H; Boedeker E C; Losonsky G; Nataro J P; Bhagat H; Edelman R
Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres.
Vaccine 1994;12(14):1270-4.
1994: Wasserman S S; Losonsky G A; Noriega F; Tacket C O; Castañeda E; Levine M M
Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
Vaccine 1994;12(11):1000-3.
1994: Huq A; Hasan J A; Losonsky G; Diomin V; Colwell R R
Colonization of professional divers by toxigenic Vibrio cholerae O1 and V. cholerae non-O1 at dive sites in the United States, Ukraine and Russia.
FEMS microbiology letters 1994;120(1-2):137-42.
1994: Losonsky G A; Wolf A; Schwalbe R S; Nataro J; Gibson C B; Lewis E W
Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;19(1):163-5.
1994: Gonzalez C; Hone D; Noriega F R; Tacket C O; Davis J R; Losonsky G; Nataro J P; Hoffman S; Malik A; Nardin E
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.
The Journal of infectious diseases 1994;169(4):927-31.
1994: Losonsky G A; Hasan J A; Huq A; Kaintuck S; Colwell R R
Serum antibody responses of divers to waterborne pathogens.
Clinical and diagnostic laboratory immunology 1994;1(2):182-5.
1993: Wasserman S S; Kotloff K L; Losonsky G A; Levine M M
Immunologic response to oral cholera vaccination in a crossover study: a novel placebo effect.
American journal of epidemiology 1993;138(11):988-93.
1993: Tacket C O; Losonsky G; Nataro J P; Cryz S J; Edelman R; Fasano A; Michalski J; Kaper J B; Levine M M
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
The Journal of infectious diseases 1993;168(6):1536-40.
1993: Edelman R; Hoffman S L; Davis J R; Beier M; Sztein M B; Losonsky G; Herrington D A; Eddy H A; Hollingdale M R; Gordon D M
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites.
The Journal of infectious diseases 1993;168(4):1066-70.
1993: Donnenberg M S; Tacket C O; James S P; Losonsky G; Nataro J P; Wasserman S S; Kaper J B; Levine M M
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection.
The Journal of clinical investigation 1993;92(3):1412-7.
1993: Gotuzzo E; Butron B; Seas C; Penny M; Ruiz R; Losonsky G; Lanata C F; Wasserman S S; Salazar E; Kaper J B
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
Infection and immunity 1993;61(9):3994-7.
1993: Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman S S; Cryz S; Kaper J B
[Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults]
Revista médica de Chile 1993;121(8):857-63.
1993: Cryz S J; Vanprapar N; Thisyakorn U; Olanratmanee T; Losonsky G; Levine M M; Chearskul S
Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children.
Infection and immunity 1993;61(3):1149-51.
1993: Losonsky G A; Tacket C O; Wasserman S S; Kaper J B; Levine M M
Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
Infection and immunity 1993;61(2):729-33.
1993: Pichichero M E; Losonsky G A
Asymptomatic infections due to wild-type rotavirus may prime for a heterotypic response to vaccination with rhesus rotavirus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(1):86-92.
1993: Pichichero M E; Marsocci S M; Francis A B; Green J L; Disney F A; Rennels M B; Lewis E D; Sugarman L; Losonsky G A; Zito E
A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants.
Vaccine 1993;11(7):747-53.
1993: Edelman R; Russell R G; Losonsky G; Tall B D; Tacket C O; Levine M M; Lewis D H
Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide).
Vaccine 1993;11(2):155-8.
1992: Panigrahi P; Losonsky G; DeTolla L J; Morris J G
Human immune response to Campylobacter jejuni proteins expressed in vivo.
Infection and immunity 1992;60(11):4938-44.
1992: Tacket C O; Losonsky G; Nataro J P; Cryz S J; Edelman R; Kaper J B; Levine M M
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
The Journal of infectious diseases 1992;166(4):837-41.
1992: Kotloff K L; Wasserman S S; O'Donnell S; Losonsky G A; Cryz S J; Levine M M
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.
Infection and immunity 1992;60(10):4430-2.
1992: Tacket C O; Binion S B; Bostwick E; Losonsky G; Roy M J; Edelman R
Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.
The American journal of tropical medicine and hygiene 1992;47(3):276-83.
1992: Cryz S J; Levine M M; Losonsky G; Kaper J B; Althaus B
Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults.
Infection and immunity 1992;60(9):3916-7.
1992: Suharyono; Simanjuntak C; Witham N; Punjabi N; Heppner D G; Losonsky G; Totosudirjo H; Rifai A R; Clemens J; Lim Y L
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Lancet 1992;340(8821):689-94.
1992: Hone D M; Tacket C O; Harris A M; Kay B; Losonsky G; Levine M M
Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
The Journal of clinical investigation 1992;90(2):412-20.
1992: Olanratmanee T; Levine M; Losonsky G; Thisyakorn V; Cryz S J
Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children.
The Journal of infectious diseases 1992;166(2):451-2.
1992: Levine M M; McEwen J; Losonsky G; Reymann M; Harari I; Brown J E; Taylor D N; Donohue-Rolfe A; Cohen D; Bennish M
Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.
Journal of clinical microbiology 1992;30(7):1636-41.
1992: Su-Arehawaratana P; Singharaj P; Taylor D N; Hoge C; Trofa A; Kuvanont K; Migasena S; Pitisuttitham P; Lim Y L; Losonsky G
Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand.
The Journal of infectious diseases 1992;165(6):1042-8.
1992: Padilla-Noriega L; Fiore L; Rennels M B; Losonsky G A; Mackow E R; Greenberg H B
Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.
Journal of clinical microbiology 1992;30(6):1392-7.
1992: Rimer H C; Wasserman S S; Flores J; Pichichero M E; Losonsky G A
Rotavirus-specific breast milk antibody in two populations and possible correlates of interference with rhesus rotavirus vaccine seroconversion.
The Journal of infectious diseases 1992;165(5):826-30.
1992: Tacket C O; Hone D M; Curtiss R; Kelly S M; Losonsky G; Guers L; Harris A M; Edelman R; Levine M M
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.
Infection and immunity 1992;60(2):536-41.
1992: Lefkowitz A; Fout G S; Losonsky G; Wasserman S S; Israel E; Morris J G
A serosurvey of pathogens associated with shellfish: prevalence of antibodies to Vibrio species and Norwalk virus in the Chesapeake Bay region.
American journal of epidemiology 1992;135(4):369-80.
1992: Tacket C O; Hone D M; Losonsky G A; Guers L; Edelman R; Levine M M
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
Vaccine 1992;10(7):443-6.
1992: Tacket C O; Losonsky G; Lubeck M D; Davis A R; Mizutani S; Horwith G; Hung P; Edelman R; Levine M M
Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine.
Vaccine 1992;10(10):673-6.
1992: Herrington D A; Losonsky G A; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman S L; Gordon D M; Levine M M; Edelman R
Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
Vaccine 1992;10(12):841-6.
1991: Herrington D A; Nardin E H; Losonsky G; Bathurst I C; Barr P J; Hollingdale M R; Edelman R; Levine M M
Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax.
The American journal of tropical medicine and hygiene 1991;45(6):695-701.
1991: Herrington D; Davis J; Nardin E; Beier M; Cortese J; Eddy H; Losonsky G; Hollingdale M; Sztein M; Levine M
Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals.
The American journal of tropical medicine and hygiene 1991;45(5):539-47.
1991: Murphy J R; Grez L; Schlesinger L; Ferreccio C; Baqar S; Muñoz C; Wasserman S S; Losonsky G; Olson J G; Levine M M
Immunogenicity of Salmonella typhi Ty21a vaccine for young children.
Infection and immunity 1991;59(11):4291-3.
1991: Hall R H; Losonsky G; Silveira A P; Taylor R K; Mekalanos J J; Witham N D; Levine M M
Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera.
Infection and immunity 1991;59(7):2508-12.
1991: Losonsky G
Infections associated with swimming and diving.
Undersea biomedical research 1991;18(3):181-5.
1991: Tacket C O; Losonsky G; Taylor D N; Baron L S; Kopecko D; Cryz S; Levine M M
Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies.
The Journal of infectious diseases 1991;163(4):901-4.
1991: Onorato I M; Modlin J F; McBean A M; Thoms M L; Losonsky G A; Bernier R H
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.
The Journal of infectious diseases 1991;163(1):1-6.
1991: Losonsky G A; D'Alessandra de Rimer H
Rotavirus specific breast milk antibody in two populations and possible correlates of protection.
Advances in experimental medicine and biology 1991;310():265-9.
1990: Tacket C O; Moseley S L; Kay B; Losonsky G; Levine M M
Challenge studies in volunteers using Escherichia coli strains with diffuse adherence to HEp-2 cells.
The Journal of infectious diseases 1990;162(2):550-2.
1990: Rennels M B; Losonsky G A; Young A E; Shindledecker C L; Kapikian A Z; Levine M M
An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group.
American journal of diseases of children (1960) 1990;144(5):601-4.
1990: Ketley J M; Kaper J B; Herrington D A; Losonsky G; Levine M M
Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.
Infection and immunity 1990;58(5):1481-4.
1990: Pichichero M E; Losonsky G A; Rennels M B; Disney F A; Green J L; Francis A B; Marsocci S M
Effect of dose and a comparison of measures of vaccine take for oral rhesus rotavirus vaccine. The Maryland Clinical Studies Group.
The Pediatric infectious disease journal 1990;9(5):339-44.
1990: Morris J G; Takeda T; Tall B D; Losonsky G A; Bhattacharya S K; Forrest B D; Kay B A; Nishibuchi M
Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans.
The Journal of clinical investigation 1990;85(3):697-705.
1990: Losonsky G A; Reymann M
The immune response in primary asymptomatic and symptomatic rotavirus infection in newborn infants.
The Journal of infectious diseases 1990;161(2):330-2.
1989: Di John D; Wasserman S S; Torres J R; Cortesia M J; Murillo J; Losonsky G A; Herrington D A; Stürcher D; Levine M M
Effect of priming with carrier on response to conjugate vaccine.
Lancet 1989;2(8677):1415-8.
1989: Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G
Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
Infection and immunity 1989;57(11):3261-4.
1989: Kotloff K L; Losonsky G A; Morris J G; Wasserman S S; Singh-Naz N; Levine M M
Enteric adenovirus infection and childhood diarrhea: an epidemiologic study in three clinical settings.
Pediatrics 1989;84(2):219-25.
1988: Kotloff K L; Wasserman S S; Steciak J Y; Tall B D; Losonsky G A; Nair P; Morris J G; Levine M M
Acute diarrhea in Baltimore children attending an outpatient clinic.
The Pediatric infectious disease journal 1988;7(11):753-9.
1988: Herrington D A; Hall R H; Losonsky G; Mekalanos J J; Taylor R K; Levine M M
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans.
The Journal of experimental medicine 1988;168(4):1487-92.
1988: Levine M M; Kaper J B; Herrington D; Losonsky G; Tacket C; Tall B
The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers.
The Southeast Asian journal of tropical medicine and public health 1988;19(3):401-15.
1988: Levine M M; Tacket C O; Herrington D; Losonsky G; Murphy J; Ferreccio C
The current status of typhoid vaccine development and clinical trials with typhoid vaccines.
The Southeast Asian journal of tropical medicine and public health 1988;19(3):459-69.
1988: Levine M M; Kaper J B; Herrington D; Ketley J; Losonsky G; Tacket C O; Tall B; Cryz S
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
Lancet 1988;2(8609):467-70.
1988: Losonsky G A; Rennels M B; Lim Y; Krall G; Kapikian A Z; Levine M M
Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006.
The Pediatric infectious disease journal 1988;7(6):388-93.
1988: Tacket C O; Losonsky G; Link H; Hoang Y; Guesry P; Hilpert H; Levine M M
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.
The New England journal of medicine 1988;318(19):1240-3.
1988: Vial P A; Kotloff K L; Losonsky G A
Molecular epidemiology of rotavirus infection in a room for convalescing newborns.
The Journal of infectious diseases 1988;157(4):668-73.
1988: Levine M M; Kaper J B; Herrington D; Losonsky G; Morris J G; Clements M L; Black R E; Tall B; Hall R
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.
Infection and immunity 1988;56(1):161-7.
1987: Nash T E; Herrington D A; Losonsky G A; Levine M M
Experimental human infections with Giardia lamblia.
The Journal of infectious diseases 1987;156(6):974-84.
1987: Murphy J R; Baqar S; Muñoz C; Schlesinger L; Ferreccio C; Lindberg A A; Svenson S; Losonsky G; Koster F; Levine M M
Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions.
The Journal of infectious diseases 1987;156(6):1005-9.
1987: Losonsky G A; Ferreccio C; Kotloff K L; Kaintuck S; Robbins J B; Levine M M
Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers.
Journal of clinical microbiology 1987;25(12):2266-9.
1987: Shaw R D; Fong K J; Losonsky G A; Levine M M; Maldonado Y; Yolken R; Flores J; Kapikian A Z; Vo P T; Greenberg H B
Epitope-specific immune responses to rotavirus vaccination.
Gastroenterology 1987;93(5):941-50.
1987: Herrington D A; Clyde D F; Losonsky G; Cortesia M; Murphy J R; Davis J; Baqar S; Felix A M; Heimer E P; Gillessen D
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
Nature 1987;328(6127):257-9.
1987: Black R E; Levine M M; Clements M L; Losonsky G; Herrington D; Berman S; Formal S B
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
The Journal of infectious diseases 1987;155(6):1260-5.
1987: Levine M M; Herrington D; Murphy J R; Morris J G; Losonsky G; Tall B; Lindberg A A; Svenson S; Baqar S; Edwards M F
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.
The Journal of clinical investigation 1987;79(3):888-902.
1987: Rennels M B; Losonsky G A; Shindledecker C L; Hughes T P; Kapikian A Z; Levine M M
Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children.
The Pediatric infectious disease journal 1987;6(3):260-4.
1986: Losonsky G A; Vonderfecht S L; Eiden J; Wee S B; Yolken R H
Homotypic and heterotypic antibodies for prevention of experimental rotavirus gastroenteritis.
Journal of clinical microbiology 1986;24(6):1041-4.
1986: Rennels M B; Losonsky G A; Levine M M; Kapikian A Z
Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children.
Pediatric infectious disease 1986;5(5):587-8.
1986: Levine M M; Losonsky G; Herrington D; Kaper J B; Tacket C; Rennels M B; Morris J G
Pediatric diarrhea: the challenge of prevention.
Pediatric infectious disease 1986;5(1 Suppl):S29-43.
1986: Losonsky G A; Rennels M B; Kapikian A Z; Midthun K; Ferra P J; Fortier D N; Hoffman K M; Baig A; Levine M M
Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants.
Pediatric infectious disease 1986;5(1):25-9.
1985: Losonsky G A; Johnson J P; Winkelstein J A; Yolken R H
Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis.
The Journal of clinical investigation 1985;76(6):2362-7.
1985: Eiden J; Losonsky G A; Johnson J; Yolken R H
Rotavirus RNA variation during chronic infection of immunocompromised children.
Pediatric infectious disease 1985;4(6):632-7.
1985: Yolken R H; Losonsky G A; Vonderfecht S; Leister F; Wee S B
Antibody to human rotavirus in cow's milk.
The New England journal of medicine 1985;312(10):605-10.
1984: Losonsky G A; Santosham M; Sehgal V M; Zwahlen A; Moxon E R
Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population.
Pediatric infectious disease 1984;3(6):539-47.
1983: Ogra P L; Losonsky G A; Fishaut M
Colostrum-derived immunity and maternal-neonatal interaction.
Annals of the New York Academy of Sciences 1983;409():82-95.
1982: Losonsky G A; Fishaut J M; Strussenberg J; Ogra P L
Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions.
The Journal of infectious diseases 1982;145(5):661-6.
1982: Losonsky G A; Fishaut J M; Strussenberg J; Ogra P L
Effect of immunization against rubella on lactation products. I. Development and characterization of specific immunologic reactivity in breast milk.
The Journal of infectious diseases 1982;145(5):654-60.
1982: Peri B A; Theodore C M; Losonsky G A; Fishaut J M; Rothberg R M; Ogra P L
Antibody content of rabbit milk and serum following inhalation or ingestion of respiratory syncytial virus and bovine serum albumin.
Clinical and experimental immunology 1982;48(1):91-101.
1981: Losonsky G A; Ogra P L
Maternal-neonatal interactions and human breast milk.
Progress in clinical and biological research 1981;70():171-82.
1981: Ogra P L; Yamanaka T; Losonsky G A
Local immunologic defenses in the genital tract.
Progress in clinical and biological research 1981;70():381-94.

Sign-in to see more